Abstract 277P
Background
Cetuximab in combination with platinum and 5-fluorouracil is the standard of care in the first-line treatment of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, this seems too toxic for patients with frailty. Our study evaluated the efficacy and safety of tegafur/uracil (UFUR) associated with platinum and cetuximab (UPEx) in frail patients with R/M HNSCC.
Methods
Our study recruited frail patients who were aged > 70 years or performance status (PS) >2. Patients with a histologically confirmed R/M HNSCC unsuitable for locoregional curative therapy were treated with UPEx. The doses of UPEx were Tegafur 200mg twice per day for 14 days, cisplatin 30mg/m(2) at day 1 and cetuximab 500mg/m(2) at day 1, repeated every 2 weeks until progression or unacceptable toxicity. For patients with unfit renal function, carboplatin AUC =2 was used instead of cisplatin. The objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) was estimated.
Results
Forty-two patients were enrolled, including 81% aged > 70 years and 19% PS >2. The primary tumor mainly located in hypopharynx (43%) and oral cavity (43%), followed by oropharynx (10%) and larynx (4%). The ORR was 67%. Median OS and PFS were, respectively, 9.7 months (95% CI 7.4-11.9) and 5.8 months (95% CI 5.1-6.5). No patients had grade 3/4 adverse effects leading to discontinue treatment in our study.
Conclusions
The UPEx regimen was effective and tolerable as first-line treatment in frail patients with R/M HNSCC.
Clinical trial identification
Editorial acknowledgement
The authors thank the heda and neck cancer working group at E-Da hospital for their great assistance of data reviewing and examining.
Legal entity responsible for the study
Meng-che Hsieh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Lymph nodes metastasis is the most important factor associated with pattern of recurrence following curative resection of gastric adenocarcinoma
Presenter: Fu-Hai Wang
Session: e-Poster Display Session
144P - Clinical implication of DNA damage response gene in patients with stage II or III gastric cancer
Presenter: In Gyu Hwang
Session: e-Poster Display Session
145P - A nomogram for predicting the benefit of adjuvant chemotherapy after resection in patients with Borrmann type IV gastric cancer
Presenter: Qing-Zhu Qiu
Session: e-Poster Display Session
146P - Red cell distribution width and mean corpuscular volume ratio as a promising new marker for chemotherapy effects in remnant gastric cancer: An analysis of a multi-institutional database
Presenter: Kai-Xiang Xu
Session: e-Poster Display Session
147P - Can the clinical stage of the 8th edition of the Union for International Cancer Control TNM classification stratify prognosis of patients with Siewert type II/III cancer?
Presenter: Hayato Watanabe
Session: e-Poster Display Session
148P - MCV-the ideal answer to predict the prognosis of remnant gastric cancer: An analysis from a multi-institutional database
Presenter: Kai Weng
Session: e-Poster Display Session
149P - Molecular and clinical characteristics of patients with resectable gastric cancer
Presenter: Zhi Zheng
Session: e-Poster Display Session
150P - Real-world assessment of the treatment patterns associated with unresectable advanced and metastatic gastric cancer in China
Presenter: Xiao Sun
Session: e-Poster Display Session
151P - Treatment patterns, healthcare resource use, economic and survival outcomes associated with unresectable advanced metastatic gastric cancers in Taiwan
Presenter: Chee Jen Chang
Session: e-Poster Display Session
152P - ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation
Presenter: Koji Kase
Session: e-Poster Display Session